Compare FDP & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDP | IVA |
|---|---|---|
| Founded | 1886 | 2011 |
| Country | Cayman Islands | France |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 1997 | 2020 |
| Metric | FDP | IVA |
|---|---|---|
| Price | $39.61 | $6.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $16.20 |
| AVG Volume (30 Days) | 223.5K | ★ 626.0K |
| Earning Date | 02-18-2026 | 09-29-2025 |
| Dividend Yield | ★ 3.06% | N/A |
| EPS Growth | ★ 413.60 | N/A |
| EPS | ★ 1.64 | N/A |
| Revenue | ★ $4,316,000,000.00 | $19,929,536.00 |
| Revenue This Year | $1.82 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.87 | ★ N/A |
| Revenue Growth | ★ 0.94 | N/A |
| 52 Week Low | $26.50 | $2.18 |
| 52 Week High | $40.75 | $7.98 |
| Indicator | FDP | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 66.61 | 56.25 |
| Support Level | $36.79 | $6.76 |
| Resistance Level | $38.49 | $7.20 |
| Average True Range (ATR) | 0.86 | 0.38 |
| MACD | 0.27 | -0.02 |
| Stochastic Oscillator | 95.23 | 49.77 |
Fresh Del Monte Produce Inc is an integrated producer, marketer & distributor of fresh-cut fruit & vegetables. It operates in three segments, Fresh and value-added products segment, which includes pineapples, fresh-cut fruit, fresh-cut vegetables, melons, vegetables, non-tropical fruit, other fruit and vegetables, avocados, and prepared foods, Banana segment & Other products and services segment, including the third-party freight & logistic services business & the Jordanian poultry and meats business. The majority is from the Fresh and value-added products segment. Geographically, it operates in North America, Europe, Asia, the Middle East, and Other, out of which the highest is from North America.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.